GON SA ATZETI
Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due…GON SA EZETI-10
Primary Hypercholesterolaemia: Ezetimibe co-administered with an HMG-CoA reductase inhibitor (statin) is indicated as adjunctive therapy to diet for use in patients with primary (heterozygous familial…NASRIX
NASRIX is indicated as an adjunct to diet in the treatment of primary hypercholesterolemia (heterozygous familial and non-familial) hyperlipidemia or mixed hyperlipidemia, and the combination…
Davipharm
